Clinical Trial Update: Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ [Phase 4]

View source ↗

Summary

Phase 4 study assessing a fifth dose of DAPTACEL in 4- to 6-year-olds previously immunized with PENTACEL. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Pertussis
• Poliomyelitis
• Tetanus

Drugs mentioned

• DAPTACEL (Diphtheria Tetanus Acellular Pertussis Vaccine Adsorbed)
• Pentacel (DTaP-Hib-IPV vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 4 | Status: COMPLETED | Results posted: 2010-01-12